Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 104

Sort by

Sort Order Select

Journal Articles

The ELEMENT-MDS Trial: A Phase 3 Randomized Study Evaluating Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Non-Transfusion-Dependent, Lower-Risk Myelodysplastic Syndromes

Amer M. Zeidan, Rami S. Komrokji, Rena Buckstein, Valeria Santini, Shelonitda Rose, Priya Malini, Glen Lew, Dimple Aggarwal, Karen L. Keeperman, Huijing Jiang, Ana Carolina Giuseppi, Jennie Zhang, Thomas Cluzeau, Jake Shortt, Uwe Platzbecker

Blood (2023) 142 (Supplement 1): 6503.

https://doi.org/10.1182/blood-2023-178635

Published: 2023

Journal Articles

The Impact of Clonal Hematopoiesis on Clinical Outcomes and Clonal Dynamics in Older Lymphoma Patients Receiving Chemotherapy

Rena Buckstein, Olivia Lopes, Amy J. M. McNaughton, Matthew C. Cheung, Lee Mozessohn, Lisa Chodirker, Kevin Imrie, Neil Berinstein, Signy Chow, Gillian Kupakuwana-Suk, Anne Parmentier, Prasha Sasitharakumar, Hubert Tsui, Liying Zhang, Michael J. Rauh

Blood (2023) 142 (Supplement 1): 442.

https://doi.org/10.1182/blood-2023-187778

Published: 2023

Journal Articles

Outcomes of Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes (AML-MRC) Receiving Intensive Vs. Non-Intensive First Line Treatment

Signy Chow, Alexandra Misura, Olga Bigun, Sila Usta, Renato Sasso, Dylan Gowlett-Park, Katarina Czibere, Rena Buckstein, Lee Mozessohn, Lisa Chodirker, James Kennedy, Hubert Tsui

Blood (2023) 142 (Supplement 1): 5840.

https://doi.org/10.1182/blood-2023-188464

Published: 2023

Journal Articles

Canadian Cancer Trials Group SC.26 - Emotion and Symptom-Focused Engagement (EASE): A Multi-Site Randomized Controlled Trial of an Intervention for Individuals with Acute Leukemia

Troy Climans, Camilla Zimmermann, Annette E. Hay, Harriet Richardson, Pierre Villeneuve, Lee Mozessohn, Andre C. Schuh, Janique Dyba, Breffni Hannon, David Lee, Rena Buckstein, Argin Malakian, Kyle Fitzgibbon, Joel Lefebvre, Wei Tu, Gary Rodin

Blood (2023) 142 (Supplement 1): 1494.

https://doi.org/10.1182/blood-2023-174378

Published: 2023

Journal Articles

Reclassification of Ascertain (ASTX727-02) Myelodysplastic Syndrome (MDS) Patients: Outcomes Including Clinical Response, Overall Survival (OS), and Leukemia Free Survival (LFS) Based on IPSS-R and IPSS-M Scoring Systems

Blood (2023) 142 (Supplement 1): 4619.

https://doi.org/10.1182/blood-2023-188258

Published: 2023

Journal Articles

Long-Term Evaluation of Luspatercept in Erythropoiesis-Stimulating Agent (ESA)-Intolerant/Refractory Patients (pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Phase 3 MEDALIST Study

Valeria Santini, Rami S. Komrokji, Guillermo Garcia-Manero, Rena Buckstein, Esther Natalie Oliva, Karen L. Keeperman, Shelonitda Rose, Ana Carolina Giuseppi, Valerie Vilmont, Yinzhi Lai, Dimana Miteva, Barkha Aggarwal, Uwe Platzbecker, Pierre Fenaux, Amer M. Zeidan

Blood (2023) 142 (Supplement 1): 915.

https://doi.org/10.1182/blood-2023-178546

Published: 2023

Journal Articles

Data-Driven Harmonization of 2022 Who and ICC Classifications of Myelodysplastic Syndromes/Neoplasms (MDS): A Study By the International Consortium for MDS (icMDS)

Luca Lanino, Somedeb Ball, Jan Philipp Bewersdorf, Monia Marchetti, Giulia Maggioni, Erica Travaglino, Najla H Al Ali, Pierre Fenaux, Uwe Platzbecker, Valeria Santini, Maria Diez-Campelo, Avani M Singh, Akriti Gupta Jain, Luis E. Aguirre, Sara M. Tinsley-Vance, Zaker I. Schwabkey, Onyee Chan, Zhuoer Xie, Andrew M. Brunner, Andrew T. Kuykendall, John M. Bennett, Rena Buckstein, Rafael Bejar, Hetty E. Carraway, Amy E. DeZern, Elizabeth A. Griffiths, Stephanie Halene, Robert Hasserjian, Jeffrey Lancet, Alan F. List, Sanam Loghavi, Olatoyosi Odenike, Eric Padron, Mrinal M. Patnaik, Gail J. Roboz, Maximilian Stahl, Mikkael A. Sekeres, David Peter Steensma, Michael R. Savona, Justin Taylor, Mina Xu, Kendra Sweet, David A Sallman, Stephen D. Nimer, Christopher S. Hourigan, Andrew H. Wei, Elisabetta Sauta, Saverio D'Amico, Gianluca Asti, Gastone Castellani, Uma M. Borate, Guillermo Sanz, Fabio Efficace, Steven D. Gore, Tae Kon Kim, Naval Daver, Guillermo Garcia-Manero, María Rozman, Alberto Orfao, Sa A. Wang, M. Kathy Foucar, Ulrich Germing, Torsten Haferlach, Phillip Scheinberg, Yasushi Miyazaki, Marcelo Iastrebner, Austin Kulasekararaj, Thomas Cluzeau, Shahram Kordasti, Arjan A. van de Loosdrecht, Lionel Ades, Amer M. Zeidan, Rami S. Komrokji, Matteo Giovanni Della Porta

Blood (2023) 142 (Supplement 1): 998.

https://doi.org/10.1182/blood-2023-186580

Published: 2023

Journal Articles

Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes

Blood (2023) 141 (17): 2047–2061.

https://doi.org/10.1182/blood.2022018604

Published: 2023

Includes: Supplemental data

Journal Articles

Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts

Blood (2022) 140 (20): 2170–2174.

https://doi.org/10.1182/blood.2022016171

Published: 2022

Includes: Supplemental data

Journal Articles

Prolonged Survival in Bi-Allelic TP53 -Mutated ( TP53 mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)

Blood (2022) 140 (Supplement 1): 2066–2069.

https://doi.org/10.1182/blood-2022-163841

Published: 2022

Journal Articles

Chromatin Architecture Protein CTCF Plays a Role in Determining 5-Azacytidine Response of Leukemic Cells By Potentially Regulating Hoxb Genes

Aparna Gopal, Derek Tam, Ryan J. Stubbins, Kieran O'Neill, Marion Shadbolt, Deborah Deng, Rena Buckstein, Aly Karsan

Blood (2022) 140 (Supplement 1): 5850–5851.

https://doi.org/10.1182/blood-2022-170674

Published: 2022

Journal Articles

Evaluation of Infection in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Systematic Review

Anna R. Blankstein, Neelan Sriranjan, Nora Choi, Kristjan Paulson, David Sanford, Lee Mozessohn, Donald S. Houston, Emily Rimmer, Sylvain Lother, Asher Mendelson, Allan Garland, Rena Buckstein, Annette E. Hay, Ryan Zarychanski, Brett L. Houston

Blood (2022) 140 (Supplement 1): 6092–6093.

https://doi.org/10.1182/blood-2022-170961

Published: 2022

Journal Articles

Evaluation of Bleeding and Thrombocytopenia in Older Adults with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Systematic Review and Meta-Analysis

Neelan Sriranjan, Anna R. Blankstein, Nora Choi, Kristjan Paulson, David Sanford, Lee Mozessohn, Donald S. Houston, Emily Rimmer, Sylvain Lother, Asher Mendelson, Allan Garland, Rena Buckstein, Annette E. Hay, Ryan Zarychanski, Brett L. Houston

Blood (2022) 140 (Supplement 1): 11632–11633.

https://doi.org/10.1182/blood-2022-171047

Published: 2022

Journal Articles

Multiple Episodes of Transfusion Independence with Luspatercept Treatment and the Impact of Dose Escalation in Patients with Lower-Risk Myelodysplastic Syndromes from the MEDALIST Study

Uwe Platzbecker, Valeria Santini, Rami S. Komrokji, Amer M. Zeidan, Guillermo Garcia-Manero, Rena Buckstein, Esther Natalie Oliva, Veronika Pozharskaya, Xianwei Ha, Jose Alberto Nadal, Dimana Miteva, Pierre Fenaux

Blood (2022) 140 (Supplement 1): 6971–6973.

https://doi.org/10.1182/blood-2022-157487

Published: 2022

Journal Articles

CCUS and Low-Risk MDS Are Inherently Similar, Sharing Clonal and Clinical Features

Christina K Ferrone, Amy JM McNaughton, Iran Rashedi, Rena Buckstein, Hubert Tsui, Michael J Rauh

Blood (2022) 140 (Supplement 1): 6915–6916.

https://doi.org/10.1182/blood-2022-169710

Published: 2022

Journal Articles

Overall Survival and Progression-Free Survival of Patients Following Luspatercept Treatment in the MEDALIST Trial

Valeria Santini, Pierre Fenaux, Amer M. Zeidan, Rami S. Komrokji, Rena Buckstein, Esther Natalie Oliva, Xianwei Ha, Dimana Miteva, Aylin Yucel, Jose Alberto Nadal, Uwe Platzbecker

Blood (2022) 140 (Supplement 1): 4079–4081.

https://doi.org/10.1182/blood-2022-157489

Published: 2022

Journal Articles

Supportive Care Strategies in Myelodysplastic Syndromes and Acute Myeloid Leukemia in Older Adults: A National Survey of Canadian Hematologists

Anna R. Blankstein, Nora Choi, Lee Mozessohn, David Sanford, Kristjan Paulson, Emily Rimmer, Donald S. Houston, Sylvain Lother, Asher Mendelson, Allan Garland, Ryan Zarychanski, Annette E. Hay, Rena Buckstein, Brett L. Houston

Blood (2022) 140 (Supplement 1): 11656–11657.

https://doi.org/10.1182/blood-2022-164450

Published: 2022

Journal Articles

Evaluation of Infection in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A Systematic Review

Jiayu Yang, Nora Choi, Lee Mozessohn, David Sanford, Kristjan Paulson, Donald S. Houston, Emily Rimmer, Sylvain Lother, Asher Mendelson, Allan Garland, Rena Buckstein, Annette E. Hay, Ryan Zarychanski, Brett L. Houston

Blood (2022) 140 (Supplement 1): 12317–12318.

https://doi.org/10.1182/blood-2022-170652

Published: 2022

Journal Articles

Evaluation of Bleeding and Thrombocytopenia in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A Systematic Review

Jiayu Yang, Nora Choi, Kristjan Paulson, David Sanford, Lee Mozessohn, Donald S. Houston, Emily Rimmer, Sylvain Lother, Asher Mendelson, Allan Garland, Rena Buckstein, Annette E. Hay, Ryan Zarychanski, Brett L. Houston

Blood (2022) 140 (Supplement 1): 12315–12316.

https://doi.org/10.1182/blood-2022-170553

Published: 2022

Journal Articles

Characterization of Patients with Lower-Risk Myelodysplastic Syndromes Experiencing Long-Term Responses with Luspatercept in the MEDALIST Study

Uwe Platzbecker, Valeria Santini, Rami S. Komrokji, Amer M. Zeidan, Guillermo Garcia-Manero, Rena Buckstein, Esther Natalie Oliva, Dimana Miteva, Veronika Pozharskaya, Xianwei Ha, Jose Alberto Nadal, Pierre Fenaux

Blood (2022) 140 (Supplement 1): 9808–9810.

https://doi.org/10.1182/blood-2022-157486

Published: 2022

NARROW

The ELEMENT-MDS Trial: A Phase 3 Randomized Study Evaluating Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Non-Transfusion-Dependent, Lower-Risk Myelodysplastic Syndromes

The Impact of Clonal Hematopoiesis on Clinical Outcomes and Clonal Dynamics in Older Lymphoma Patients Receiving Chemotherapy

Outcomes of Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes (AML-MRC) Receiving Intensive Vs. Non-Intensive First Line Treatment

Canadian Cancer Trials Group SC.26 - Emotion and Symptom-Focused Engagement (EASE): A Multi-Site Randomized Controlled Trial of an Intervention for Individuals with Acute Leukemia

Reclassification of Ascertain (ASTX727-02) Myelodysplastic Syndrome (MDS) Patients: Outcomes Including Clinical Response, Overall Survival (OS), and Leukemia Free Survival (LFS) Based on IPSS-R and IPSS-M Scoring Systems

Long-Term Evaluation of Luspatercept in Erythropoiesis-Stimulating Agent (ESA)-Intolerant/Refractory Patients (pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Phase 3 MEDALIST Study

Data-Driven Harmonization of 2022 Who and ICC Classifications of Myelodysplastic Syndromes/Neoplasms (MDS): A Study By the International Consortium for MDS (icMDS)

Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes

Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts

Prolonged Survival in Bi-Allelic TP53 -Mutated ( TP53 mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)

Chromatin Architecture Protein CTCF Plays a Role in Determining 5-Azacytidine Response of Leukemic Cells By Potentially Regulating Hoxb Genes

Evaluation of Infection in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Systematic Review

Evaluation of Bleeding and Thrombocytopenia in Older Adults with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Systematic Review and Meta-Analysis

Multiple Episodes of Transfusion Independence with Luspatercept Treatment and the Impact of Dose Escalation in Patients with Lower-Risk Myelodysplastic Syndromes from the MEDALIST Study

CCUS and Low-Risk MDS Are Inherently Similar, Sharing Clonal and Clinical Features

Overall Survival and Progression-Free Survival of Patients Following Luspatercept Treatment in the MEDALIST Trial

Supportive Care Strategies in Myelodysplastic Syndromes and Acute Myeloid Leukemia in Older Adults: A National Survey of Canadian Hematologists

Evaluation of Infection in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A Systematic Review

Evaluation of Bleeding and Thrombocytopenia in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A Systematic Review

Characterization of Patients with Lower-Risk Myelodysplastic Syndromes Experiencing Long-Term Responses with Luspatercept in the MEDALIST Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only